The company had posted a net profit of Rs 62.42 crore for the same period of previous fiscal.
Net sales of the company rose to Rs 356.28 crore for the third quarter as compared to Rs 292.59 crore for the same period of corresponding financial year, Ajanta Pharma Ltd said in a filing to the BSE.
"All our growth drivers are performing as per our plans and expectations. We continue to post above industry growth in India and emerging markets in our branded generic business segment," Ajanta Pharma joint managing director Rajesh Agrawal said.
The company's Dahej (Gujarat) formulation facility implementation has been completed and is undergoing qualification, he added.
"We expect to take regulatory filing batches from Q1 FY16 onwards. Addition of this facility will ensure that we have adequate capacities to cater to our growths in coming years," Mr Agrawal said.
Ajanta Pharma shares were trading 11.25 per cent up at Rs 2,665.15 apiece during afternoon session on the BSE.